Maribavir
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Maribavir: From Cytomegalovirus Infection to Bronchitis
One-Sentence Summary
Maribavir is an oral antiviral that is registered in Singapore as LIVTENCITY film-coated tablets. The TxGNN model predicts it may be effective for bronchitis, but there are currently 0 clinical trials and 0 publications supporting this prediction. The prediction rests on a computational graph score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the Singapore licence data compiled for this report |
| Predicted New Indication | Bronchitis |
| TxGNN Prediction Score | 87.79% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data was not available in the data compiled for this report. Based on the mechanistic assessment provided, maribavir is a benzimidazole riboside that inhibits the human cytomegalovirus (HCMV) UL97 protein kinase. This blocks viral DNA replication, maturation and nuclear egress. Its activity is specific to CMV.
Bronchitis is mostly caused by other respiratory viruses or bacteria, so no direct mechanistic link has been established. The high TxGNN score (0.878) reflects graph-based proximity only. One narrow, speculative connection is CMV-associated lower respiratory infection in immunocompromised patients, but the available data do not support it.
Other top-ranked predictions are also unsupported by mechanism or evidence. These include severe nonproliferative diabetic retinopathy (79.11%), bronchial neoplasm (77.78%), diabetic retinopathy (76.24%), filariasis (74.26%), and several colorectal or colonic conditions (73.1%–73.4%). All are L5 (model prediction only) with a Hold recommendation.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN17208P | LIVTENCITY FILM-COATED TABLET 200MG | Tablet, film coated (oral) | Not stated in the data compiled |
Safety Considerations
Please refer to the package insert for safety information. No warnings, contraindications, or drug interaction records were available in the data compiled for this report. Retrieval of the package insert remains outstanding.
Conclusion and Next Steps
Decision: Hold
Rationale: The bronchitis prediction is supported only by a model score. There are no clinical trials or publications, and no plausible mechanistic link, since maribavir's activity is specific to CMV. Safety data are also incomplete, so the candidate cannot advance to safety screening.
To proceed, the following is needed:
- The HSA package insert (warnings, contraindications, approved indication) to complete safety screening
- Mechanism-of-action data from DrugBank
- Any clinical or preclinical evidence for maribavir in bronchitis, such as CMV-related lower respiratory infection in immunocompromised patients
- Route compatibility and similarity-to-original-indication assessments, both currently pending
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.